ОЦЕНКА ПОПУЛЯЦИОННОГО ИММУНИТЕТА К ВИРУСУ SARS-COV-2 СРЕДИ НАСЕЛЕНИЯ Г. ГРОДНО
Аннотация
В г. Гродно, как и в целом в Республике Беларусь, активными темпами проводится вакцинация населения против COVID-19. Цель работы. Оценка популяционного иммунитета к вирусу SARS-CoV-2 среди населения г. Гродно. Материал исследования. Сыворотка крови 422 пациентов, жителей г. Гродно. Результаты. Высокий показатель серопозитивности (94,7%) установлен среди лиц, ранее не болевших COVID-19 и вакцинированных «Спутник V», наименьший – в группе не болевших инфекцией лиц и не вакцинированных – 25%. Оценка концентрации антител с учетом возрастной категории обследуемых не выявила достоверных изменений их уровня. Установлено, что с учетом временного интервала, у лиц, независимо от того, болели они или не болели COVID-19, но привитых вакциной «Спутник V», уровень антител максимально высок на втором месяце после последней дозы вакцины, снижается к четвертому месяцу после вакцинации и сохраняется на данном уровне до полугода.
Литература
Popova AYu, Andreeva EE, Babura EA, Balakhonov SV, Bashketova NS, Bulanov MV, Valeullina NN, Goryaev DV, Detkovskaya NN, Ezhlova EB, Zaitseva NN, Istorik OA, Kovalchuk IV, Kozlovskikh DN, Kombarova SV, Kurganova OP, Kutyrev VV, Lomovtsev AE, Lukicheva LA, Lyalina LV, Melnikova AA, Mikailova OM, Noskov AK, Noskova LN, Oglezneva EE, et al. Osobennosti formirovanija seroprevalentnosti naselenija Rossijskoj Federacii k nukleokapsidu SARS-CoV-2 v pervuju volnu jepidemii Covid-19 [Features of developing sarscov-2 nucleocapsid protein population-based seroprevalence during the first wave of the Covid-19 epidemic in the Russian Federation]. Infektsiya i immunitet [Russian Journal of Infection and Immunity]. 2021;11(2):297-323. https://doi.org/10.15789/2220-7619-FOD-1684. (Russian).
Clemente-Suárez VJ, Hormeño-Holgado A, Jiménez M, Benitez-Agudelo JC, Navarro-Jiménez E, Perez-Palencia N, Maestre-Serrano R, Laborde-Cárdenas CC, TorneroAguilera JF. Dynamics of Population Immunity Due to the Herd Effect in the Covid-19 Pandemic. Vaccines. 2020;8(2):236. https://doi.org/10.3390/vaccines8020236.
Xia Y, Zhong L, Tan J, Zhang Z, Lyu J, Chen Y, Zhao A, Huang L, Long Z, Liu NN, Wang H, Li S. How to Understand “Herd Immunity” in Covid-19 Pandemic. Front Cell Dev Biol. 2020;8:547314. https://doi.org/10.3389/fcell.2020.547314.
Randolph HE, Barreiro LB. Herd Immunity: Understanding Covid-19. Immunity. 2020;52(5):737-741. https://doi.org/10.1016/j.immuni.2020.04.012.
Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of Covid-19 vaccine acceptance in the US. EClinicalMedicine. 2020;26:100495. https://doi.org/10.1016/j.eclinm.2020.100495.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-897. https://doi.org/10.1016/S0140-6736(20)31866-3.
MacDonald NE, Comeau J, Dubé E, Bucci L, Graham JE. A public health timeline to prepare for Covid-19 vaccines in Canada. Can J Public Health. 2020;111(6):945-952. https://doi.org/10.17269/s41997-020-00423-1.
Vignesh R, Shankar EM, Velu V, Thyagarajan SP. Is Herd Immunity Against SARS-CoV-2 a Silver Lining? Front Immunol. 2020;11:586781. https://doi.org/10.3389/fimmu.2020.586781.
Popova AYu, Ezhlova EB, Melnikova AA, Danilova TE, Bulanov MV, Lyalina LV, Smirnov VS, Totolyan AA. Analiz seroprevalentnosti k SARS-CoV-2 sredi naselenija Vladimirskoj oblasti v period jepidemii Covid-19 [Analysis of seroprevalence to SARS-CoV-2 in population of Vladimir Region during Covid-19 epidemic]. Jepidemiologija i infekcionnye bolezni. Aktualnye voprosy [Epidemiology and infectious diseases. Current items]. 2021;11(2):29-35. https://doi.org/10.18565/epidem.2021.11.2.29-35. (Russian).
Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27(2):taaa021. https://doi.org/10.1093/jtm/taaa021.
Balakhonov SV, Dubrovina VI, Pyatidesyatnikova AB, Briukhova DD, Kiseleva NO, Korytov KM, Voitkova VV, Perezhogin AN, Chesnokova MV, Gavrilova TA, Seledtcov AA. Dinamika izmenenij populjacionnogo immuniteta k virusu SARS-CoV-2 u zhitelej Irkutskoj oblasti v uslovijah pandemii Covid-19 [Dynamics of changes in population immunity to the SARS-CоV-2 virus in residents the Irkutsk region in the context of the COVID-19 pandemic]. Jepidemiologija i Vakcinoprofilaktika [Epidemiology and Vaccinal Prevention]. 2021;20(2):12-17. https://doi.org/10.31631/2073-3046-2021-20-2-12-17. (Russian).
Popova AYu, Yezhlova EB, Melnikova AA, Andreeva EE, Kombarova SyU, Lyalina LV, Smirnov VS, Aleshkin AV, Kobzeva YV, Ignatova EN, Osadchaya MN, Nazarenko EV, Antipova LN, Basov AA, Zatevalov LM, Novikova LI, Bochkareva VS, Likhanskaya EI, Lomonosova VI, Totolian AA, Gracheva NM, Shmeleva EA, Manuilov BM, Lyutov AG. Kollektivnyj immunitet k SARS-CoV-2 zhitelej Moskvy v jepidemicheskij period Covid-19 [Collective immunity to SARS-COV-2 of Moscow residents during the covid-19 epidemic period]. Infekcionnye bolezni [Infectious diseases]. 2020;18(4):8-16. https://doi.org/10.20953/1729-9225-2020-4-8-16. (Russian).
Popova AYu, Ezhlova EB, Melnikova AA, Historik OA, Mosevich OS, Lyalina LV, Smirnov VS, Cherny MA, Balabysheva NS, Loginova IS, Vladimirova OS, Samoglyadova IS, Vasev NA, Rumyantseva SV, Chupalova EYu, Selivanova GV, Muraviova MV, Timofeeva LV, Khankishieva EN, Tylchevskaya VD, Nikitenko ND, Kostenitskaya TI, Virkunen NV, Klimkina IM, Kuzmina TM, et al. Ocenka populjacionogo immuniteta k SARSCoV-2 sredi naselenija Leningradskoj oblasti v period jepidemii Covid-19 [Assessment of the herd immunity to SARS-COV-2 among the population of the Leningrad region during the Covid-19 epidemic]. Problemy osobo opasnyh infekcij [Problems of Particularly Dangerous Infections]. 2020;3:114-123. https://doi.org/10.21055/0370-1069-2020-3-114-123. (Russian).
Popova AYu, Ezhlova EB, Melnikova AA, Noskov AK, Kovalev EV, Karpushchenko GV, Lyalina LV, Smirnov VS, Chemisova OS, Trishina AV, Bereznyak EA, Volovikova SV, Stenina SI, Yanovich EG, Meloyan MG, Asmolova NYu, Usova AA, Slis SS, Totolyan AA. Ocenka populjacionnogo immuniteta k SARS-CoV-2 na territorii Rostovskoj oblasti [Assessment of population immunity to SARS-COV-2 virus in the Rostov region]. Problemy osobo opasnyh infekcij [Problems of Particularly Dangerous Infections]. 2020;4:117-124. https://doi.org/10.1016/j.clim.2020.108448 (Russian).
Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. Covid-19: Immunology and treatment options. Clin Immunol. 2020;215:108448. https://doi.org/10.1016/j.clim.2020.108448.
Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, Ko WC, Hsueh PR. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020;53(3):404-412. https://doi.org/10.1016/j.jmii.2020.02.012.
Ministerstvo zdravoohranenija Respubliki Belarus. Rekomendacii po vakcinacii protiv Covid-19 (dopolnennaja redakcija) [Internet]. Available from: http://minzdrav.gov.by/ru/dlya-spetsialistov/rekomendatsii-po-vaktsinatsii-protiv-covid-19.php (Russian).
Vsemirnaja organizacija zdravoohranenija. Koronavirus Covid-19 [Internet]. Available from: https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019 (Russian).
